Stryker (NYSE:SYK) Director Ronda Stryker Sells 276,173 Shares of Stock

Stryker Corporation (NYSE:SYK) Director Ronda Stryker sold 276,173 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Stryker Price Performance

NYSE:SYK opened at $355.74 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a fifty day moving average price of $374.63 and a 200 day moving average price of $380.99. The stock has a market cap of $136.04 billion, a P/E ratio of 47.12, a PEG ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Needham & Company LLC upped their price target on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a report on Monday. UBS Group set a $408.00 target price on Stryker in a research note on Monday, October 13th. Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Finally, Evercore ISI lowered their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Fourteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $433.37.

Institutional Trading of Stryker

Several large investors have recently added to or reduced their stakes in the company. Mar Vista Investment Partners LLC lifted its stake in shares of Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock valued at $33,572,000 after acquiring an additional 8,353 shares during the period. United Services Automobile Association bought a new stake in Stryker during the 1st quarter worth about $2,857,000. Hendley & Co. Inc. lifted its position in Stryker by 60.3% during the 2nd quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock valued at $5,546,000 after purchasing an additional 5,274 shares during the period. AXS Investments LLC boosted its stake in shares of Stryker by 13.7% in the 1st quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock valued at $3,286,000 after purchasing an additional 1,062 shares during the last quarter. Finally, Park Edge Advisors LLC acquired a new stake in shares of Stryker during the 2nd quarter worth approximately $679,000. 77.09% of the stock is owned by institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.